BioRestorative Therapies (BRTX) Payables (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Payables came in at $2.7 million in Q4 2025, down 8.76% YoY from $3.0 million in Q4 2024, and down 3.09% on a QoQ basis from $2.8 million in Q3 2025.
BioRestorative Therapies (BRTX) Payables (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Payables data on file, last reported at $2.7 million in Q4 2025.
- Quarterly Payables fell 8.76% year-over-year to $2.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.7 million (down 8.76% YoY) and the FY2025 annual result came in at $2.7 million, down 8.76% from the prior year.
- Payables fell to $2.7 million in Q4 2025, from $2.8 million in the prior quarter.
- In the past five years, Payables ranged from a high of $14.4 million in Q1 2022 to a low of $50827.0 in Q4 2021.
- A 5-year average of $4.2 million and a median of $3.1 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2021 — Payables plunged 97.56% — and 2022, when it jumped 11139.37%.
- Tracing BRTX's Payables over 5 years: stood at $50827.0 in 2021, then jumped by 11139.37% to $5.7 million in 2022, then sank by 69.66% to $1.7 million in 2023, then surged by 73.3% to $3.0 million in 2024, then decreased by 8.76% to $2.7 million in 2025.
- The last three Payables figures came in at $2.7 million (Q4 2025), $2.8 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 108.02 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 428.93 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 35.57 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 622.65 Mn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 2.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.74 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 3.75 Mn |
| Dec 31, 2024 | 3.00 Mn |
| Sep 30, 2024 | 3.86 Mn |
| Jun 30, 2024 | 4.71 Mn |
| Mar 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 1.73 Mn |
| Sep 30, 2023 | 2.29 Mn |
| Jun 30, 2023 | 10.03 Mn |
| Mar 31, 2023 | 7.12 Mn |
| Dec 31, 2022 | 5.71 Mn |
| Sep 30, 2022 | 7.69 Mn |
| Jun 30, 2022 | 6.81 Mn |
| Mar 31, 2022 | 14.42 Mn |
| Dec 31, 2021 | 50,827.00 |
| Sep 30, 2021 | 124,558.00 |
| Jun 30, 2021 | 97,692.00 |
| Mar 31, 2021 | 245,661.00 |